---
schema_version: "secwatch.filing_event.v1"
accession: "0001831868-25-000011"
form_type: "8-K/A"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:23:48.563015+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical Q2 net loss $2.0M on $0.3M revenue; NEUTRALIZE-AKI trial 60% enrolled

## Summary
- Net loss of $2.0M ($0.18/share) vs $3.2M ($1.03/share) in Q2 2024; revenue from QUELIMMUNE pediatric SCD was $0.3M.
- NEUTRALIZE-AKI pivotal trial enrollment reached 125 of 200 patients (60%+); interim DSMB recommendations expected Q3 2025.
- Added three new top children's hospital customers; SAVE Surveillance Registry showed 75% 28-day survival in first 20 patients.
- Raised total $20.8M through offerings in June ($12.4M), July and August 2025 ($8.4M) to extend cash runway into 2026.

## SEC filing metadata
- accession: 0001831868-25-000011
- form_type: 8-K/A
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000183186825000011/0001831868-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000183186825000011/icu-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831868-25-000011
- JSON: https://secwatch.observer/filing/0001831868-25-000011.json
- Plain text: https://secwatch.observer/filing/0001831868-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.